Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Review the use of new and emerging lipid-lowering agents targeted to lowering lipoprotein(a), now recognized as an independent risk factor for premature atherosclerotic disease.
The new classes of glucose-lowering drug have shown beneficial cardiovascular effects, including antihypertensive properties. Review and compare their BP-lowering potential in this paper.
Many considerations influence decisions on optimal duration of therapy with DAPT in patients with CAD, especially those with multiple comorbidities or undergoing interventional procedures.
This paper provides practical advice on risk stratification, antithrombotic prophylaxis, and antiplatelet/anticoagulant treatments in patients at risk of or hospitalized with SARS-CoV-2 infection.
Coagulation abnormalities have emerged as a common pathology in COVID-19. This paper presents a look at the pathogenesis, clinical features, and management of hypercoagulability in COVID-19 patients.
Long-Term Antithrombotic Therapy and Clinical Outcomes in Patients with Acute Coronary Syndrome and Renal Impairment: Insights from EPICOR and EPICOR Asia.
Mission Statement:
The American Journal of Cardiovascular Drugs promotes rational therapy and disease management within the discipline of cardiology by providing a regular program of independent review articles covering all aspects of the management of cardiovascular disorders, particularly the place in therapy of newer and established agents and procedures.
